Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

被引：7
|
作者：
Fjorden, Karin [1 ]
Ekberg, Sara [2 ]
Kuric, Nevzeta [3 ]
Smedby, Karin E. [4 ,5 ]
Lagerlof, Ingemar [6 ]
Larsen, Thomas S. [7 ]
Jorgensen, Judit M. [8 ]
de Nully Brown, Peter [9 ]
Jerkeman, Mats [1 ]
机构：
[1] Lund Univ, Skane Univ Hosp, Dept Oncol, Lund, Sweden
[2] Karolinska Inst, Dept Med Solna, Div Clin Epidemiol, Stockholm, Sweden
[3] Halmstad Cty Hosp, Dept Hematol, Halmstad, Sweden
[4] Karolinska Inst, Div Hematol, Dept Med Solna, Stockholm, Sweden
[5] Karolinska Univ Hosp, Stockholm, Sweden
[6] Linkoping Univ, Dept Med & Hlth Sci, Div Drug Res, Linkoping, Sweden
[7] Odense Univ Hosp, Dept Haematol, Odense, Denmark
[8] Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark
[9] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 196卷 / 02期
关键词：
Idelalisib; relapsed; refractory DLBCL; transformed lymphoma; IBRUTINIB;
D O I：
10.1111/bjh.17792
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：437 / 440
页数：4
相关论文
共 50 条
  • [31] HEALTH UTILITY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (RR-DLBCL) PATIENTS - RESULTS OF A PHASE II TRIAL WITH ORAL SELINEXOR
    Casasnovas, R. O.
    Daniele, P.
    Tremblay, G.
    Maerevoet, M.
    Zijlstra, J.
    Follows, G.
    Vermaat, J. S. P.
    Kalakonda, N.
    Goy, A. H.
    Choquet, S.
    Van den Neste, E.
    Hill, B. T.
    Thieblemont, C.
    Cavallo, F.
    de la Cruz, F.
    Kuruvilla, J.
    Hamad, N.
    Bouabdallah, R.
    Jaeger, U.
    Caimi, P.
    Gurion, R.
    Warzocha, K.
    Bakhshi, S.
    Sancho, J. M.
    Schuster, M.
    Egyed, M.
    Offner, F.
    Vasilakopoulos, T.
    Samal, P.
    Nagy, A.
    Ku, M.
    Canales Albendea, M. A.
    VALUE IN HEALTH, 2020, 23 : S479 - S480
  • [32] A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
    Yazbeck, Victor
    Shafer, Danielle
    Perkins, Edward B.
    Coppola, Domenico
    Sokol, Lubomir
    Richards, Kristy L.
    Shea, Thomas
    Ruan, Jia
    Parekh, Samir
    Strair, Roger
    Flowers, Christopher
    Morgan, David
    Kmieciak, Maciej
    Bose, Prithviraj
    Kimball, Amy
    Badros, Ashraf Z.
    Baz, Rachid
    Lin, Hui-Yi
    Zhao, Xiuhua
    Reich, Richard R.
    Tombes, Mary Beth
    Shrader, Ellen
    Sankala, Heidi
    Roberts, John D.
    Sullivan, Daniel
    Grant, Steven
    Holkova, Beata
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09): : 569 - +
  • [33] A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
    Holkova, Beata
    Perkins, Edward B.
    Sokol, Lubomir
    Richards, Kristy L.
    Parekh, Samir
    Elstrom, Rebecca
    Badros, Ashraf Z.
    Espinoza-Delgado, Igor
    Schell, Michael J.
    Kimball, Amy
    Tombes, Mary Beth
    Shrader, Ellen
    Sankala, Heidi
    Coppola, Domenico
    Kmieciak, Maciej
    Sullivan, Daniel
    Roberts, John D.
    Grant, Steven
    BLOOD, 2011, 118 (21) : 353 - 354
  • [34] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
    Palomba, M. Lia
    Till, Brian G.
    Park, Steven I.
    Morschhauser, Franck
    Cartron, Guillaume
    Marks, Reinhard
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Popplewell, Leslie L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
  • [35] A phase 2 study of bortezomib in relapsed/refractory diffuse large B-Cell lymphoma (DLBCL).
    de Vos, S
    Fernando, D
    Schenkein, DP
    Rosen, PJ
    BLOOD, 2005, 106 (11) : 267B - 267B
  • [36] Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study
    Palomba, Maria Lia
    Cartron, Guillaume
    Popplewell, Leslie
    Ribrag, Vincent
    Westin, Jason
    Huw, Ling-Yuh
    Agarwal, Shefali
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Morschhauser, Franck
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 504 - 512
  • [37] FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    不详
    AMERICAN HEALTH AND DRUG BENEFITS, 2020, 13 (05): : 214 - 214
  • [38] Efficacy of Salvage Radiotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Wang, S.
    Chen, J. Y.
    Cao, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E471 - E472
  • [39] Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
    Graf, Solomon A.
    Cassaday, Ryan D.
    Morris, Karolyn
    Voutsinas, Jenna M.
    Wu, Qian Vicky
    Behnia, Sanaz
    Lynch, Ryan C.
    Krakow, Elizabeth
    Rasmussen, Heather
    Chauncey, Thomas R.
    Kanan, Sandra
    Soma, Lorinda
    Smith, Stephen D.
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 176 - 181
  • [40] Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Juarez-Salcedo, Luis Miguel
    Nimkar, Santosh
    Corazon, Ana Maria
    Dalia, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
12345